Cannabis Stocks Falter as FDA Shares Conflicting Views on CBD After Regulatory Hearing
The fate of recent wellness rockstar, CBD—a cannabis derivative—remains unknown as the FDA debates regulation amidst growing public demand.
MORE STORIES LIKE THIS
RF Investment Partners and Burlington Capital Join Forces to Acquire Top Precision Garage Door Franchise
The Penny Shortage Is Creating a New Risk for QSR Franchise Systems
Possible Pizza Hut Sale Signals Shift in Yum! Brands’ Franchise Strategy
Large Domino’s Franchisee Files for Chapter 11 Bankruptcy
Featured Franchise News
Featured Brand News
/story1/2710152/ac08af5307423338edf3f61ad81ca9518948.jpg)

/story1/2731656/1773358186_2731656.png)
/story1/2731725/3e4af8a5bb3baad6721bcaac9c3b1ac8563.jpg)
/story1/2731599/1892c6e35f792878e270881ca55c97975627.jpg)
/story1/2731708/1773859098_2731708.png)
/story1/2731789/d76f696d98f4448608a8c5f19a6a00328630.jpg)
/story1/2731776/71bf117b8a393788b222f3d603b06ec34229.jpg)
/story1/2731783/5cd056dffc231554daf62e1049e53b5c3015.jpg)
/story1/2731728/1773960518_2731728.png)
/story1/2731792/1774561023_2731792.png)
/story1/2731791/1774559673_2731791.png)
/story1/2731786/1143a883bc580516d4d985dd2f904ac31794.jpg)
/story1/2731784/e08d6ea55cf199125527582138771dce1104.jpg)